Teva Pharmaceuticals Schizophrenia Drug Delivery Trial Shows Improvement in Social Functioning

MT Newswires Live

Nov 02, 2024

Teva Pharmaceutical Industries (TEVA) US affiliate Teva Pharmaceuticals said Friday that TEV-'749 showed significant improvement in social functioning and quality of life at week eight in adult patients with schizophrenia.

The data is from the acute treatment portion of the phase 3 clinical subcutaneous olanzapine extended-release injection study, according to the company.

The company said no new safety signals for drug delivery method were identified and no post-injection delirium/sedation syndrome events were reported.

Interim results for a phase 1 trial show that the drug delivery method may help prevent the development of post-injection delirium/sedation syndrome, Teva added.

Price: 18.49, Change: +0.05, Percent Change: +0.27

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2480851970"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480851970\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2480851970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-02 03:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480851970","market":"fut","top_or_hot":-1,"title":"Teva Pharmaceuticals Schizophrenia Drug Delivery Trial Shows Improvement in Social Functioning","media":"MT Newswires Live","content":"<html><body><p> Teva Pharmaceutical Industries (TEVA) US affiliate Teva Pharmaceuticals said Friday that TEV-'749 showed significant improvement in social functioning and quality of life at week eight in adult patients with schizophrenia.</p><p>The data is from the acute treatment portion of the phase 3 clinical subcutaneous olanzapine extended-release injection study, according to the company.</p><p>The company said no new safety signals for drug delivery method were identified and no post-injection delirium/sedation syndrome events were reported.</p><p>Interim results for a phase 1 trial show that the drug delivery method may help prevent the development of post-injection delirium/sedation syndrome, Teva added.</p><p>Price: 18.49, Change: +0.05, Percent Change: +0.27</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceuticals Schizophrenia Drug Delivery Trial Shows Improvement in Social Functioning</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceuticals Schizophrenia Drug Delivery Trial Shows Improvement in Social Functioning\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-02 03:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Teva Pharmaceutical Industries (TEVA) US affiliate Teva Pharmaceuticals said Friday that TEV-'749 showed significant improvement in social functioning and quality of life at week eight in adult patients with schizophrenia.</p><p>The data is from the acute treatment portion of the phase 3 clinical subcutaneous olanzapine extended-release injection study, according to the company.</p><p>The company said no new safety signals for drug delivery method were identified and no post-injection delirium/sedation syndrome events were reported.</p><p>Interim results for a phase 1 trial show that the drug delivery method may help prevent the development of post-injection delirium/sedation syndrome, Teva added.</p><p>Price: 18.49, Change: +0.05, Percent Change: +0.27</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2480851970","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480851970","pubTimestamp":1730489652,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Teva Pharmaceutical Industries  US affiliate Teva Pharmaceuticals said Friday that TEV-'749 showed significant improvement in social functioning and quality of life at week eight in adult patients with schizophrenia.The data is from the acute treatment portion of the phase 3 clinical subcutaneous olanzapine extended-release injection study, according to the company.The company said no new safety signals for drug delivery method were identified and no post-injection delirium/sedation syndrome events were reported.Interim results for a phase 1 trial show that the drug delivery method may help prevent the development of post-injection delirium/sedation syndrome, Teva added.Price: 18.49, Change: +0.05, Percent Change: +0.27","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药","BK4559":"巴菲特持仓","BK4584":"避孕概念","BK4007":"制药","BK4566":"资本集团","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4557":"大麻股"},"translate_title":"梯瓦制药精神分裂症药物递送试验显示社会功能改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical Industries (TEVA) US affiliate Teva Pharmaceuticals said Friday that TEV-'749 showed significant improvement in social functioning and quality of life at week eight in adult patients with schizophrenia.The data is from the acute treatment portion of the phase 3 clinical subcutaneous olanzapine extended-release injection study, according to the company.The company said no new safety signals for drug delivery method were identified and no post-injection delirium/sedation syndrome events were reported.Interim results for a phase 1 trial show that the drug delivery method may help prevent the development of post-injection delirium/sedation syndrome, Teva added.Price: 18.49, Change: +0.05, Percent Change: +0.27","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}